Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

CellCourier: programmable drug delivery via combinatorial cell targeting and generative design of tailored binding peptides

Project description

Revolutionary mRNA delivery enabling precise cell targeting

Conventional mRNA delivery methods often suffer from off-target effects, leading to unintended side effects. The ERC-funded CellCourier project aims to revolutionise mRNA delivery by enabling precise targeting of specific cell types through a platform that integrates single-cell genomics, computational modelling, and generative AI. The project will design peptide binders for lipid nanoparticles or self-assembling vehicles using unique surface codes derived from the Human Cell Atlas. Validation will occur both in silico and in vitro, with a focus on lung conditions such as COPD, cystic fibrosis, and lung cancer. Additionally, the project intends to secure intellectual property rights for its innovations and explore commercialisation opportunities to advance targeted therapeutics and personalised medicine.

Objective

CellCourier aims to revolutionize mRNA delivery by enabling precise cell-type-specific targeting through a data-driven platform that integrates single-cell genomics, computational modeling, and generative AI. Conventional approaches often suffer from off-target effects, leading to unintended side effects. To address this, CellCourier leverages combinatorial peptide binder design to achieve precise cell-type recognition, enabling next-generation delivery modalities such as LNPs or STVs.
At the core of CellCourier is a computational pipeline that defines unique surface codes for target cells using single-cell transcriptomic data from the Human Cell Atlas (HCA). This process is enhanced by Nicheformer, a model for predicting cell-cell interactions, and Prophet, a deep-learning model for multi-omics perturbation prediction—both key outcomes of the ERC AdG DeepCell grant. Using these refined surface codes, we apply our all-atom generative model to design peptide binders optimized for high specificity and stability. A competitive binding pipeline, which has shown a threefold increase in hit rates, further refines peptide selection.
The process is validated both in silico and in vitro. During the ERC Proof of Concept (PoC) period, we will focus on demonstrating feasibility by targeting the lung using insights from the Human Lung Cell Atlas (HLCA), paving the way for novel treatments for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and lung cancer.
Beyond technical validation, we will implement intellectual property (IP) protection strategies, securing patents for advanced peptide binders and their integration into innovative delivery systems. We will also explore commercialization pathways, including spin-off formation and pharmaceutical partnerships for out-license protected IP.
By providing the critical tools for precise, cell-type-specific mRNA delivery, CellCourier will establish a scalable and versatile platform, unlocking next-generation targeted therapeutics and transforming personalized medicine.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Net EU contribution
€ 150 000,00
Address
INGOLSTADTER LANDSTRASSE 1
85764 Neuherberg
Germany
Region
Bayern Oberbayern München, Landkreis
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)